Systemic Medical Treatment in Men with Metastatic Castration-Resistant Prostate Cancer: Recommendations for Daily Routine

Publisher： Karger

E-ISSN： 2296-5262|38|12|654-668

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.38, Iss.12, 2015-0, pp. : 654-668

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration‐resistant prostate cancer

By  

THE PROSTATE, Vol. 270-4137, Iss. 15, 2015-11 ,pp. : 1814-1820

John Wiley & Sons Inc

Access to resources Recommend Favorite

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration‐resistant prostate cancer

By  

THE PROSTATE, Vol. 75, Iss. 15, 2015-11 ,pp. : 1814-1820

John Wiley & Sons Inc

Access to resources Recommend Favorite

Is prostate cancer changing?: Evolving patterns of metastatic castration‐resistant prostate cancer

By  

CANCER, Vol. 120, Iss. 6, 2014-03 ,pp. : 833-839

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration‐resistant prostate cancer: A retrospective study

By  

THE PROSTATE, Vol. 78, Iss. 4, 2018-03 ,pp. : 278-278

John Wiley & Sons Inc

Access to resources Recommend Favorite

Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer

By  

Oncology, Vol. 91, Iss. 5, 2016-08 ,pp. : 267-273

Karger

Access to resources Recommend Favorite